Jul 08, 2025 09:31 JST

Source: Eisai

Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment

TOKYO, July 8, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it has been selected for the highest rating of “Supplier Engagement Leader” in the Supplier Engagement Rating by the global environmental non-profit organization CDP.(1)

The Supplier Engagement Assessment evaluates how effectively companies are working with suppliers to address climate change issues. In its responses to the CDP Climate Change Questionnaire on 'Governance', 'Targets', 'Scope 3 emissions(2)' and 'Value chain engagement', Eisai’s efforts to engage with suppliers were highly regarded, leading to this selection. To conduct environmentally conscious business activities throughout our entire supply chain, Eisai asks business partners to comply with the “Eisai Global Code of Conduct for Business Partners(3)” which clearly states Eisai’s requirement for environmental conservation. Collaboration with suppliers is also strengthened by conducting sustainability assessments of partners and providing feedback on the results.

Eisai identifies “Business activities with consideration for the global environment” as one of its material issues. Based on the “Eisai Network Companies Environmental Protection Policy”, Eisai is promoting responses to climate change as key environmental activities across the group. Eisai is working towards the realization of a decarbonized society, including receiving approval for the SBT 1.5°C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI)Race to Zero Circle, which calls for achieving net zero by 2050.(4)

Please refer to Eisai’s website for more detailed information about its environmental activities.

The preservation of the global environment is essential for realizing Eisai’s corporate concept of human health care (hhc). Eisai will contribute to empowering people to “realize their fullest lives” through our climate change initiatives.

(1)A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system.
(2)Indirect greenhouse gas emissions across the entire corporate value chain
(3)Please refer here for further details
(4)Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GASREDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050
https:/www.eisai.com/news/2024/news202412.html

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

 

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
 
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
 
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
More Press release >>

Latest Press Release


More Latest Release >>